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TargeTS for drug deVelopmeNT  
iN HiV NeuropaTHy
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Summary: There are globally ~34 million people infected with HIV. 
About 40% of those people living with HIV, whose infection is sup-
pressed by antiretroviral therapy (ART) and are often otherwise well, 
have a length-dependent distal symmetrical sensory polyneuropathy, 
which in most cases is associated with neuropathic pain. This makes 
sensory neuropathy 1 of the most prevalent clinical manifestations 
of HIV in the current era of combined ART and therefore an increas-
ingly major area of therapeutic need. Sensory neuropathy is usu-
ally attributable to either viral–neuronal interactions and/or ART 
neurotoxicity.
Data will be reviewed for:
-  the epidemiologic and risk factors of HIV-associated neuropathy
-  efficacy of current therapies: a meta-analysis of current rand-
omized controlled trials for neuropathic pain in HIV
-  sensory profiles and other clinical characteristics in HIV-positive 
patients with and without sensory neuropathy
-  laboratory animal modeling of HIV GP120-induced neuropa-
thy, including ethologically relevant complex pain behaviors and 
pharmacologic analysis
-  laboratory animal modeling of ART neurotoxicity, including 
ethologically relevant complex pain behaviors and pharmaco-
logic analysis
-  use of gene microarray studies of animals models to reveal novel 
drug targets
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Global malaria control has been threatened by resistance to 
antimalarial medicines. P falciparum resistance to chloroquine and 
pyrimethamine both originated in Southeast Asia and subsequently 
spread to Africa with substantial implications for global public health. 
Similarly, in the 1980s, resistance to mefloquine emerged rapidly on 
the western border of Cambodia and on the northwest border of 
Thailand only a few years after its introduction. In April 2001, WHO 
recommended the use of artemisinin-based combination therapies 
(ACTs), combining an artemisinin derivative, known for its rapid 
action and short elimination from the body, with another drug char-
acterized by a different mechanism of action and slow elimination.
Emerging P falciparum resistance to artemisinin derivatives is 
a major global public health concern. WHO first issued a warning 
about the threat of artemisinin resistance in the Greater Mekong sub-
region in 2005, after routine efficacy studies showed delayed clear-
ance after ACTs. The first cases of confirmed artemisinin resistance 
were found in western Cambodia, along the Cambodia–Thailand 
border in late 2006. The 4 countries most affected by the emergence 
of artemisinin resistance are Cambodia, Myanmar, Thailand, and 
Vietnam. Despite observed changes in parasite sensitivity to arte-
misinins, ACTs continue to cure patients, provided the partner drug 
is efficacious. However, once resistance to artemisinin emerges, it is 
more likely that resistance to the partner drug will also develop and 
vice versa. Currently and in absence of a molecular marker, the best 
available indicator of suspected artemisinin resistance is the propor-
tion of patients who are still parasitemic at day 3 (72 hours) after a 
full course of an ACT.
In 2010, WHO developed the Global Plan for Artemisinin 
Resistance Containment (GPARC). The plan was drafted after a con-
sultation with all constituencies of the Roll Back Malaria Partnership, 
as well as a range of donor organizations and industry partners. 
WHO is also currently implementing an emergency response plan 
to scale-up efforts to contain artemisinin resistance in the Greater 
Mekong subregion. The presentation will provide an update of the 
current status of artemsinin resistance and containment activities.
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Summary: Prescribing is a complex task and is often undertaken 
by the most inexperienced doctors. From day 1, new doctors need 
to be able to prescribe safely and rationally. It is clear that this 
requires more than traditional textbook knowledge of pharmacology. 
Preparing new graduates to be effective prescribers is 1 of the major 
concerns of modern undergraduate medical education. Evidence sug-
gests that this training could be improved, although there is debate 
about the most effective methods for doing so.
This presentation will review the perceived deficiencies of current 
teaching, the challenges of delivering effective prescribing education, 
and the available evidence on a range of teaching and learning meth-
ods. In particular, the UK British Pharmacological Society 2012 rec-
ommendations for undergraduate education in clinical pharmacology 
and therapeutics will be used as an example of how medical educators 
might approach this difficult area.
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poCkeT guide; ipad may be!
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Summary: The increased prominence of in vitro–in vivo extrapola-
tion (IVIVE) capabilities has helped with recognizing the potential of 
drug–drug interactions (DDI) at early stages of drug discovery. Latest 
regulatory guidelines by the EMA and FDA provide recommenda-
tions for conduct of IVIVE through modeling. They are designed to 
protect the public from adverse effects associated with likely DDI 
by appropriate labeling or preventing the marketing of drugs with 
unmanageable DDI. However, DDI in an individual patient are deter-
mined by a myriad of variables. Prescribers may use labels in the 
clinical practice; nonetheless, currently, labels do not provide infor-
mation for all the different permutation of conditions that put certain 
subgroup of patients at higher risk (eg, comorbid diseases, genetics, 
age and intake of several drugs). Some recent attempts by both the 
FDA and EMA have moved the focus from an average individual to 
a perceived susceptible patient (eg, chronic renal failure).
Creation of user-friendly interface computer programs of DDI 
prediction, which takes the sources of variability into account, may 
assist with the prediction and management of DDI in an individual 
patient. The required information on drugs (ie, affinity to various 
enzymes, nonenzymatic routes, permeability, protein binding, inhibi-
